Related Experiment Videos
[Heart in sickle-cell anemia (author's transl)]
Medecine Tropicale : Revue Du Corps De Sante Colonial
|March 1, 1978
Insights
Sickle-cell anemia can lead to various heart problems, including heart failure and coronary ischemia. Patient factors like sickle cell genotype and age influence these cardiac complications, despite limited therapeutic options.
Area of Science:
- Cardiology
- Hematology
- Genetics
Context:
- Sickle-cell anemia is a genetic blood disorder with known systemic complications.
- Cardiac involvement is a significant concern in patients with sickle-cell anemia.
- Understanding the specific cardiac manifestations is crucial for patient management.
Purpose:
- To outline the spectrum of cardiac complications associated with sickle-cell anemia.
- To highlight the role of genetic status (homo- or heterozygotic) and age in cardiac risk.
- To discuss the current understanding of pathogenesis and therapeutic limitations.
Summary:
- Sickle-cell anemia is linked to diverse cardiac issues such as chronic anemia-induced heart insufficiency, pseudo-rheumatic heart disease, chronic pulmonary heart disease, coronary ischemia, and cardiomyopathic syndrome.
- Both homozygous and heterozygous sickle-cell states, along with patient age, are identified as critical determinants of cardiac risk.
- While the pathogenesis of these cardiac conditions is relatively well-established, current therapeutic interventions offer limited efficacy.
Impact:
- Provides a comprehensive overview of sickle-cell anemia-related cardiac conditions for clinicians and researchers.
- Emphasizes the need for targeted cardiac monitoring and potentially novel therapeutic strategies in sickle-cell anemia patients.
- Contributes to a better understanding of genotype-phenotype correlations in sickle-cell disease, specifically concerning cardiovascular health.
Abstract:
Sickle-cell anemia may give heart troubles: heart insufficiency by chronic anemia, pseudo-rhumatic heart, chronic pulmonary heart, coronarian ischemia and cardiomyopathic syndrome. The homo or heterozygotic status and the age are important factors. A rather clear pathogenesis has been built up for these various troubles but therapy has only a limited efficiency.